Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Metab ; 36(4): 822-838.e8, 2024 Apr 02.
Article in English | MEDLINE | ID: mdl-38350448

ABSTRACT

Immunomodulatory effects of long-chain fatty acids (LCFAs) and their activating enzyme, acyl-coenzyme A (CoA) synthetase long-chain family (ACSL), in the tumor microenvironment remain largely unknown. Here, we find that ACSL5 functions as an immune-dependent tumor suppressor. ACSL5 expression sensitizes tumors to PD-1 blockade therapy in vivo and the cytotoxicity mediated by CD8+ T cells in vitro via regulation of major histocompatibility complex class I (MHC-I)-mediated antigen presentation. Through screening potential substrates for ACSL5, we further identify that elaidic acid (EA), a trans LCFA that has long been considered harmful to human health, phenocopies to enhance MHC-I expression. EA supplementation can suppress tumor growth and sensitize PD-1 blockade therapy. Clinically, ACSL5 expression is positively associated with improved survival in patients with lung cancer, and plasma EA level is also predictive for immunotherapy efficiency. Our findings provide a foundation for enhancing immunotherapy through either targeting ACSL5 or metabolic reprogramming of antigen presentation via dietary EA supplementation.


Subject(s)
Antigen Presentation , Neoplasms , Oleic Acids , Humans , CD8-Positive T-Lymphocytes/metabolism , Programmed Cell Death 1 Receptor , Dietary Supplements , Tumor Microenvironment , Coenzyme A Ligases/metabolism
2.
Nat Commun ; 14(1): 4758, 2023 08 08.
Article in English | MEDLINE | ID: mdl-37553341

ABSTRACT

Dietary methionine interventions are beneficial to apoptosis-inducing chemotherapy and radiotherapy for cancer, while their effects on ferroptosis-targeting therapy and immunotherapy are unknown. Here we show the length of time methionine deprivation affects tumoral ferroptosis differently. Prolonged methionine deprivation prevents glutathione (GSH) depletion from exceeding the death threshold by blocking cation transport regulator homolog 1 (CHAC1) protein synthesis. Whereas, short-term methionine starvation accelerates ferroptosis by stimulating CHAC1 transcription. In vivo, dietary methionine with intermittent but not sustained deprivation augments tumoral ferroptosis. Intermittent methionine deprivation also sensitizes tumor cells against CD8+ T cell-mediated cytotoxicity and synergize checkpoint blockade therapy by CHAC1 upregulation. Clinically, tumor CHAC1 correlates with clinical benefits and improved survival in cancer patients treated with checkpoint blockades. Lastly, the triple combination of methionine intermittent deprivation, system xc- inhibitor and PD-1 blockade shows superior antitumor efficacy. Thus, intermittent methionine deprivation is a promising regimen to target ferroptosis and augment cancer immunotherapy.


Subject(s)
Ferroptosis , Humans , Methionine/pharmacology , Apoptosis , Racemethionine/pharmacology , Immunotherapy , Cell Line, Tumor
3.
Ear Nose Throat J ; : 1455613221119071, 2022 Aug 24.
Article in English | MEDLINE | ID: mdl-36000487

ABSTRACT

Lipoid proteinosis (LP) is a rare inherited multisystem disease. Classical clinical features include beaded eyelid papules, laryngeal infiltration, and neurological symptoms. Here, we report the diagnosis and treatment of a female patient with LP in order to improve physician awareness and understanding of this disease.

4.
BMC Pregnancy Childbirth ; 21(1): 148, 2021 Feb 18.
Article in English | MEDLINE | ID: mdl-33602166

ABSTRACT

BACKGROUND: In the entire population, an aberrant right subclavian artery (ARSA) is closely associated with chromosomal abnormalities. ARSA with additional ultrasonic findings would increase risk of chromosomal abnormalities. The risk of fetal chromosomal abnormalities increased exponentially with the maternal age. These risks in the advanced maternal age (AMA) group are uncertain. This study aimed to determine the incidence of ARSA in Chinese AMA and non-AMA women and the frequency of aneuploidy among AMA and non-AMA women with ARSA. METHODS: This retrospective study included 13,690 singleton pregnancies, were divided into AMA and non-AMA groups. Integrated obstetric ultrasonic screening, biochemical screening, noninvasive prenatal screening, and fetal karyotype analysis were analyzed. RESULTS: The overall incidence of ARSA was 0.69%, with no difference between age groups. The incidence of chromosomal abnormalities in the AMA group (37 / 2860) was much higher than that of the non-AMA group. The risk of chromosomal abnormalities significantly increased with both ARSA detected and additional ultrasound findings. With combined ARSA and AMA, the likelihood of the incidence of chromosomal abnormalities increased. Chimerism (45X / 46XX) was found with isolated ARSA in AMA pregnancies. CONCLUSION: There is a high prevalence of chromosomal abnormalities in fetuses of AMA women. ARSA increases the risk of chromosomal abnormalities in both age groups, especially combined with ARSA. When ARSA occurs in AMA women, it confers a high likelihood of chromosomal abnormalities.


Subject(s)
Aneuploidy , Cardiovascular Abnormalities/diagnostic imaging , Chromosome Aberrations , Subclavian Artery/abnormalities , Adult , Cardiovascular Abnormalities/epidemiology , Female , Humans , Incidence , Karyotyping , Maternal Age , Pregnancy , Pregnancy Trimester, Second , Retrospective Studies , Risk Factors , Subclavian Artery/diagnostic imaging , Ultrasonography, Prenatal , Young Adult
5.
Int J Immunopathol Pharmacol ; 32: 2058738418780593, 2018.
Article in English | MEDLINE | ID: mdl-29877106

ABSTRACT

Chronic pharyngitis is characterized as a common inflammation of the pharyngeal mucosa, and anti-inflammatory medications are the common treatment to relieve it. Polysacharides of Citrus grandis L. Osbeck (PCG) and luteolin have been reported to have anti-inflammatory activities. In this study, the protective effects of PCG and luteolin on chronic pharyngitis are evaluated and the underlying mechanisms are explored. PCG and luteolin are administrated to animal models with granuloma, ear edema and chronic pharyngitis and the effects of PCG and luteolin on disease severity are evaluated. We also evaluate the effects of PCG and luteolin on inflammatory cytokine production in macrophages stimulated with lipopolysaccharides (LPS)/interferon-gamma (IFN-γ) and detect the effects of PCG and luteolin on macrophage polarization. Finally, we evaluate the effects of PCG and luteolin on activations of LPS-induced downstream signaling pathways. PCG and luteolin alleviate the disease severity of granuloma, ear edema and chronic pharyngitis. PCG and luteolin suppress the productions of pro-inflammatory cytokines interlukin-6 (IL-6), interlukin-12 (IL-12) and tumor necrosis factor alpha (TNF-α) in macrophages. Luteolin promotes macrophage M2 polarization by enhancing expressions of arginase (Arg1) and mannose receptor C type 1 (Mrc1). PCG and luteolin suppress nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation and interferon regulatory factor 1 (IRF1), interferon regulatory factor 5 (IRF5) expression. PCG together with luteolin relieves chronic pharyngitis by anti-inflammatory via suppressing NF-κB pathway and the polarization of M1 macrophage.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Citrus/chemistry , Luteolin/therapeutic use , Macrophages/drug effects , NF-kappa B/antagonists & inhibitors , Pharyngitis/drug therapy , Polysaccharides/therapeutic use , Animals , Anti-Inflammatory Agents/administration & dosage , Cell Polarity/drug effects , Cells, Cultured , Chronic Disease , Disease Models, Animal , Edema/drug therapy , Edema/immunology , Granuloma/drug therapy , Granuloma/immunology , Luteolin/administration & dosage , Male , Mice, Inbred BALB C , Mice, Inbred ICR , Pharyngitis/immunology , Polysaccharides/administration & dosage , Polysaccharides/isolation & purification , Rabbits , Rats, Wistar , Respiratory Mucosa
6.
Microb Pathog ; 113: 365-371, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29146495

ABSTRACT

Chronic pharyngitis, a common inflammation of the pharyngeal mucosa, is often caused by bacteria, viruses, alcohol abuse, overuse of the voice and cigarettes. This study aimed to explore the effects of polysaccharides of Citrus grandis L. Osbeck (PCG) in relieving chronic pharyngitis and illustrate the underlying mechanisms. Polysaccharides were obtained from PCG by column chromatographic extraction. Six clinical symptom scores, such as the severity of itchy throat, hoarseness, pain, odynophagia, cough and otalgia were evaluated in chronic pharyngitis patients after the oral intake of PCG. The effects of polysaccharides on chronic pharyngitis were investigated in ammonia-stimulated rabbits through pathology analysis. The levels of inflammatory markers in the peripheral blood T cells were analyzed by ELISA. The total and phosphorylated levels of ERK1/2, JNK and p38 were assessed by Western blot. Protein amount of IKKα and p65, IKKα/ß activity and p65 activity were evaluated by Western blot and luciferase assay. The clinical studies presented that PCG significantly relieved the six symptoms of chronic pharyngitis patients. Pathology analysis of chronic pharyngitis animals showed that the PCG treatment groups showed a significant decrease in the number of pathologic cells and the reduction of pathologic cells was dose-dependent (p < 0.01). ELISA analysis showed that PCG significantly inhibited the αCD3-induced increase of IFN-γ, IL-2 and IL-4 expression in a dose-dependent manner. Moreover, Western blot and luciferase assay suggested that the phosphorylation of IKKα/ß in peripheral blood T cells was inhibited by the administration of PCG. These results indicate that polysaccharides exhibit anti-inflammatory effects by inhibiting the phosphorylation of IKKs, subsequently suppressing the NF-κB pathway activation and decreasing the expression of inflammatory mediators.


Subject(s)
Citrus/chemistry , Inflammation/drug therapy , Pharyngitis/drug therapy , Plant Extracts/pharmacology , Polysaccharides/pharmacology , Ammonia/adverse effects , Animals , Cytokines/metabolism , Disease Models, Animal , HEK293 Cells , Humans , I-kappa B Kinase/metabolism , Interferon-gamma/metabolism , Interleukin-2/metabolism , Interleukin-4/metabolism , MAP Kinase Signaling System , Mitogen-Activated Protein Kinases/metabolism , Pharyngitis/pathology , Pharyngitis/physiopathology , Phosphorylation , Rabbits , T-Lymphocytes/drug effects , p38 Mitogen-Activated Protein Kinases
SELECTION OF CITATIONS
SEARCH DETAIL
...